Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Rottneros
Mandate

Vinge has advised Rottneros

September 06, 2017

Vinge has advised Rottneros AB (publ) (“Rottneros”) in connection with an issue of unsecured bonds up to a total amount of SEK 600 million.

The bonds have a term of five years and floating interest of STIBOR 3M + 4.15 per cent. Swedbank has acted as financial adviser and sole bookrunner in connection with the bond issue.

The proceeds from the initial bond issue will be used as part of completing the financing of the strategic plan Agenda 500 and for achieving long-term efficiency of the Group's capital structure. The bonds are, in accordance with their terms and conditions, intended to be admitted to trading on the corporate bond list of Nasdaq Stockholm.

Vinge’s team consisted of Louise Salomon together with André Isacson and Lionardo Ojeda.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026